As major employers tweak their 401(k) matching contribution schedules, opting for an annual lump-sum payment rather than per pay period, advisers are calling for more conversations with their employer clients to discuss plan design and benefit restructuring.
“We're entering a key time with most employers,” said Jim O'Shaughnessy, a managing partner at Sheridan Road Financial. “A lot of it has to do with the last decade. We're having these deeper discussions with our clients on all benefits, and the primary focus is on how the retirement benefits are coordinated with other benefits.”
Some of the largest employers match on an annual basis, according to an analysis by Bloomberg, including financial services firms that have touted the importance of retirement savings. Those firms include such household names as The Charles Schwab Corp., Citigroup Inc., Morgan Stanley and JPMorgan Chase & Co.
5 Best Small Cap Stocks To Invest In 2015: MAKO Surgical Corp.(MAKO)
MAKO Surgical Corp., a medical device company, markets its advanced robotic arm solution and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. The company?s MAKOplasty partial knee arthroplasty solution enables resurfacing of one or two specific diseased compartments of the joint, preserving more soft tissue and healthy bone of the knee; and MAKOplasty Total Hip Arthroplasty, a surgical solution that enables orthopedic surgeons to pe rform total hip arthroplasty. In addition, it offers tactile guidance system, which allows orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage unicompartmental degeneration through mid-stage multicompartmental degeneration with a modular knee implant system; and RESTORIS family of implants for use in single and bicompartmental knee resurfacing procedures. The company markets its products through direct sales force, as well as through independent orthopedic product agents and distributors. MAKO Surgical Corp. was founded in 2004 and is headquartered in Fort Lauderdale, Florida.
Advisors' Opinion:- [By Dan Caplinger]
The companies that are hit hardest by the tax are those that are already unprofitable even before paying the new levy. For up-and-coming robotics-maker MAKO Surgical (NASDAQ: MAKO ) , which has already lost $32.5 million on revenue of slightly more than $100 million over the past 12 months, imposing what could be up to $2.3 million in additional medical-device taxes not only adds insult to injury but threatens MAKO's ability to keep growing.
- [By Dan Caplinger]
Next Tuesday, MAKO Surgical (NASDAQ: MAKO ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise.
- [By Steve Symington and Alison Southwick]
On the heels of Intuitive Surgical's (NASDAQ: ISRG ) recent warning about weak capital spending in the U.S., MAKO Surgical (NASDAQ: MAKO ) investors are worried that their up-and-coming company may not be able to meet its already conservative guidance when it reports earnings later this month.
- [By John Udovich]
Small cap robotic stock Adept Technology (NASDAQ: ADEP) has put in a very good performance this month verses its immediate peer�iRobot Corporation (NASDAQ: IRBT) as well as against medical robotic stocks like MAKO Surgical (NASDAQ: MAKO), Accuray Incorporated (NASDAQ: ARAY) and Hansen Medical, Inc (NASDAQ: HNSN). I should also mention that we have recently added Adept Technology to our SmallCap Network Elite Opportunity (SCN EO) portfolio (we are up 9% since last week) because we feel robotics is an improving sector as companies aim to reduce overhead and improve efficiencies through machine to machine (M2M) automation.
5 Best Industrial Disributor Stocks To Buy Right Now: Saes Getters SpA (SG&A)
SAES Getters SpA is an Italy-based company primarily engaged in the production of getters and metal dispensers. The Company structures its business into three main units: Industrial Applications, which includes getters and metal dispensers used in light sources and electron vacuum devices, getters for microelectronic and micromechanical systems, pumps for vacuum systems, getters for solar collectors, products for thermal insulation, and gas purifier systems; Shape Memory Alloys, which includes shape memory alloy semi-finished products, components and devices for medical and industrial applications, and Information Displays, which includes getters and metal dispensers for liquid crystal displays, and barium getters for cathode ray tubes. Additionally, through the Business Development Unit, the Company produces dryers and getters for organic light-emitting diode (OLED), sealants for solar panels and energy storage getter devices. Advisors' Opinion:- [By Jason Rivera]
To help facilitate this destruction of value has been that Koss has bought back a lot of its shares as the company has been overvalued. The below quote is from its most recent annual report.
In April of 1995, the Board of Directors approved a stock repurchase program authorizing the Company to purchase from time to time up to $2,000,000 of its common stock for its own account. Subsequently, the Board of Directors periodically has approved increases in the stock repurchase program. As of June 30, 2012, the most recently approved increase was for additional purchases of $2,000,000, which occurred in October of 2006, for an aggregate maximum of $45,500,000, of which $43,360,247 had been expended through June 30, 2012 . No purchases were made during the year ended June 30, 2012. The Company intends to effect all stock purchases either on the open market or through privately negotiated transactions and intends to finance all stock purchases through its own cash flow or by borrowing for such purchases.As you can see from this page, most of KOSS' margins have dropped substantially since 2007. Especially of note is its operating margin, ROE and ROIC. Book value per share, cash flow per share, revenue and working capital have all dropped substantially as well. Normally when I have evaluated companies' cost of goods sold rising is what has caused the above metrics to drop, but that has stayed relatively stable over the years at KOSS. The culprit in this case is selling, general and administrative (SG&A) related expenses expressed below as a percentage of its sales. The following numbers were taken from Morningstar: - [By GURUFOCUS]
For investors, Qualcomm understand the benefits of cloud services. It seems there are numerous questions unresolved. Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, initiating overhauls of its R&D and selling, general and administrative (SG&A) segments for Pharma. A company willing to build their capabilities, and open to a new view of value will likely achieve better outcomes. Delivering support, personalization, scalability, speed and flexibility are attractive areas for growth.
5 Best Industrial Disributor Stocks To Buy Right Now: Opexa Therapeutics Inc.(OPXA)
Opexa Therapeutics, Inc., a biopharmaceutical company, develops patient-specific cellular therapies for the treatment of autoimmune diseases. Its principal product includes Tovaxin, a personalized cellular immunotherapy treatment that completed Phase IIb clinical study for multiple sclerosis. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is based in The Woodlands, Texas.
Advisors' Opinion:- [By CRWE]
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), reported that the Company is rebranding its leading MS therapy with the new name Tcelna(TM).
5 Best Industrial Disributor Stocks To Buy Right Now: United States Natural Gas Fund LP (UNG)
United States Natural Gas Fund, LP (USNG) is a limited partnership. The Company is a commodity pool that issues limited partnership interests (units) traded on the NYSE Arca, Inc. (the NYSE Arca). The investment objective of USNG is for the changes in percentage terms of its units��net asset value (NAV) to reflect the changes in percentage terms of the spot price of natural gas delivered at the Henry Hub, Louisiana as measured by the changes in the Futures Contract on natural gas traded on the New York Mercantile Exchange (NYMEX) that is the near month contract to expire, except when the near month contract is within two weeks of expiration, in which case the futures contract will be the next month contract to expire. The Company�� general partner is United States Commodity Funds LLC (the General Partner) and is responsible for the management of USNG.
USNG invests in futures contracts for natural gas, crude oil, heating oil, gasoline, and other petroleum-based fuels that are traded on the NYMEX, ICE Futures or other United States and foreign exchanges (collectively, Futures Contracts). USNG also invests in other natural gas-related investments, such as cash-settled options on Futures Contracts, forward contracts for natural gas, cleared swap contracts, and over-the-counter transactions that are based on the price of natural gas, oil and other petroleum-based fuels, Futures Contracts and indices based on the foregoing (collectively, Other Natural Gas-Related Investments). USNG invests in Natural Gas Interests to the fullest extent possible. In pursuing this objective, the primary focus of the General Partner is the investment in Futures Contracts and the management of USNG�� investments in short-term obligations of the United States of two years or less (Treasuries), cash and/or cash equivalents for margining purposes and as collateral.
Advisors' Opinion:- [By Paul Ausick]
The U.S. Natural Gas Fund (NYSEMKT: UNG) is down 1.4%, at $19.03 in a 52-week range of $16.59 to $24.09. The Market Vectors Oil Services ETF (NYSEMKT: OIH) is up 1.2%, at $46.34 in a 52-week range of $36.24 to $46.78. The first fund tracks spot prices; the second includes major drillers and services companies.
- [By Paul Ausick]
The U.S. Natural Gas Fund (NYSEMKT: UNG) is down 1.2%, at $18.56 in a 52-week range of $16.59 to $24.09. The Market Vectors Oil Services ETF (NYSEMKT: OIH) is down 0.6%, at $45.45 in a 52-week range of $36.24 to $46.78. The first fund tracks spot prices; the second includes major drillers and services companies.
- [By Charles Sizemore]
But be careful here. Given the abundant new supplies of natural gas coming to market, natural gas prices should stay depressed for a long time to come, this short-term spike notwithstanding. Another factor to consider is contango, which is common problem for commodity ETFs and ETNs. When a market is in contango, investors lose money every month when they roll over their futures contracts in what is called a ��egative roll yield.��This might be tolerable when prices are rising rapidly. But it can come as a shock to the uninitiated trader. Contango has been a major drag on the returns of the United States Natural Gas Fund (UNG), for instance.
No comments:
Post a Comment